Up­dat­ed: A week af­ter GSK pulls one Ze­ju­la in­di­ca­tion, FDA sets ODAC meet­ing to re­view re­vis­ing la­bel fur­ther

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee will meet on Nov. 22 to dis­cuss whether to pull an in­di­ca­tion for GSK’s ovar­i­an can­cer drug Ze­ju­la, con­sid­er­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER